The global circulating tumor cells (CTC) liquid biopsy market is experiencing significant growth during the forecast period of 2023-2030. The market is driven by the growing demand for CTC liquid biopsy due to its effectiveness in cancer detection and monitoring. The increasing prevalence of cancer, influenced by genetic disorders, lifestyle changes, and alcohol consumption, further boosts the market's growth. The utilization of CTC for patient screening and preclinical studies of cancer drugs adds to its popularity. The introduction of nanotechnology for improved sensitivity and efficiency, widespread adoption of CTC-based liquid biopsy, and rising demand for minimally invasive diagnostic procedures contribute to the market's expansion.
According to Data Bridge Market Research the Global Circulating Tumor Cells (CTC) Liquid Biopsy Market which was USD 1,173.84 million in 2022, is expected to reach USD 4,170.06 million by 2030, growing at a CAGR of 17.17% during the forecast period of 2023 to 2030.
“Rising prevalence of cancer facilitate market growth”
The rising prevalence of cancer is a major driver of the global circulating tumor cells (CTC) liquid biopsy market. Cancer remains a significant global health concern, with increasing cases reported each year. Liquid biopsies offer a non-invasive and convenient approach for early cancer detection, monitoring treatment response, and assessing disease progression. The ability to capture and analyze CTCs from blood samples provides valuable insights into tumor biology and personalized treatment strategies. As the demand for accurate and efficient cancer diagnostics and monitoring tools grows, the CTC liquid biopsy market is expected to experience significant growth in the coming years.
What restraints the growth of the global circulating tumor cells (CTC) liquid biopsy market?
“The lower sensitivity of certain liquid biopsies”
The lower sensitivity of certain liquid biopsies is a significant restraint of the global circulating tumor cells (CTC) liquid biopsy market. While liquid biopsies offer non-invasive and convenient methods for cancer detection and monitoring, their sensitivity can vary depending on the type and stage of cancer. In some cases, the level of circulating tumor cells in the blood may be too low to be reliably detected, leading to false-negative results. Improving the sensitivity and accuracy of liquid biopsies is crucial to address this limitation and enhance their clinical utility in cancer diagnostics and treatment monitoring.
Segmentation: Global Circulating Tumor Cells (CTC) Liquid Biopsy Market
The circulating tumor cells (CTC) liquid biopsy market is segmented on the basis of technology, application, clinical application, sample type, product, specimen, and end user.
- On the basis of technology, the circulating tumor cells (CTC) liquid biopsy market is segmented into CTC detection methods, CTC enrichment methods, EX vivo positive selection, molecular (RNA)-based technologies, functional in vitro cell invasion assay, xenotransplantation models, microchips, single spiral microchannel, negative selection and immunocytochemical technologies.
- On the basis of application, the circulating tumor cells (CTC) liquid biopsy market is segmented into cancer application, non-cancer applications, non-invasive prenatal testing (NIPT), organ transplantation infectious disease testing.
- On the basis of clinical application, the circulating tumor cells (CTC) liquid biopsy market is segmented into early cancer screening, diagnosis, therapy selection, treatment monitoring, prognosis and recurrence monitoring.
- On the basis of sample type, the circulating tumor cells (CTC) liquid biopsy market is segmented into blood, urine, saliva, cerebrospinal fluid, others.
- On the basis of product, the circulating tumor cells (CTC) liquid biopsy market is segmented into kits and reagents, blood collection tubes, devices or system.
- On the basis of specimen, the circulating tumor cells (CTC) liquid biopsy market is segmented into blood, bone marrow, and other body fluids.
- On the basis of end user, the circulating tumor cells (CTC) liquid biopsy market is segmented into research and academic institutes, reference laboratories and hospitals, and physician laboratories.
Regional Insights: North America dominates the Global Circulating Tumor Cells (CTC) Liquid Biopsy Market
North America holds a dominant position in the global circulating tumor cells (CTC) liquid biopsy market, primarily driven by the widespread adoption of liquid biopsy techniques for cancer diagnosis in the region. The rising incidence of cancer cases in the US has contributed significantly to North America's market leadership. The region's advanced healthcare infrastructure and a strong emphasis on early cancer detection and personalized medicine have further bolstered the adoption of liquid biopsy technologies.
Asia Pacific is projected to witness substantial growth during the forecast period from 2023 to 2030. The market's expansion in this region is attributed to various factors, including increasing disposable income, growing awareness about liquid biopsy techniques, and greater adoption of advanced diagnostic technologies in hospitals, clinics, and diagnostic laboratories. Additionally, the rising healthcare expenditure and improved accessibility to hospitals and diagnostic centers are driving the adoption of liquid biopsy methods, further fueling the market's growth in the Asia Pacific.
To know more about the study visit, https://www.databridgemarketresearch.com/reports/global-circulating-tumor-cells-ctc-liquid-biopsy-market
Recent Developments in Global Circulating Tumor Cells (CTC) Liquid Biopsy Market
- In November 2021, Myriad Genetics, Inc. revealed its data presentation at the San Antonio Breast Cancer Symposium, underscoring the value of genetic testing in breast cancer treatment. This development positions Myriad Genetics, Inc. to introduce novel products in the market, contributing to the growth of the liquid biopsy market.
- In February 2021, Menarini Silicon Biosystems launched its CellMag product line for manual enrichment and staining of circulating tumor cells. This expansion of its product offerings has strengthened Menarini Silicon Biosystems' position in the market and is expected to have a significant impact on the growth of the liquid biopsy market.
The Prominent Key Players Operating in the Global Circulating Tumor Cells (CTC) Liquid Biopsy Market Include:
- QIAGEN (Germany)
- Bio-Techne (U.S.)
- Precision Medical Group, LLC. (U.S.)
- Aviva Systems Biological Corporation (U.S.)
- Biocept, Inc. (U.S.)
- Fluxion Biosciences, Inc. (U.S.)
- Greiner Bio-One International GmbH (Austria)
- Ikonisys (U.S.)
- Miltenyi Biotec (Germany)
- IVDiagnostics (U.S.)
- BioFluidica (U.S.)
- Canopus Medical (Sweden)
- Biolidics Limited (Singapore)
- Creativ MicroTech, Inc. (U.S.)
- LungLife AI, Inc. (U.S.)
- Epic Sciences (U.S.)
- Rarecells Diagnostics (France)
- ScreenCell (France)
- Menarini Silicon Biosystems (U.S.)
Above are the key players covered in the report, to know about more and exhaustive list of global circulating tumor cells (CTC) liquid biopsy market companies contact, https://www.databridgemarketresearch.com/contact
Research Methodology: Global Circulating Tumor Cells (CTC) Liquid Biopsy Market
Data collection and base year analysis are done using data collection modules with large sample sizes. The market data is analyzed and estimated using market statistical and coherent models. In addition, market share analysis and key trend analysis are the major success factors in the market report. The key research methodology used by DBMR research team is data triangulation which involves data mining, analysis of the impact of data variables on the market, and primary (industry expert) validation. Apart from this, data models include Vendor Positioning Grid, Market Time Line Analysis, Market Overview and Guide, Company Positioning Grid, Company Market Share Analysis, Standards of Measurement, global vs Regional and Vendor Share Analysis. Please request analyst call in case of further inquiry.
